Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonoscopy | 14 | 2023 | 60 | 4.320 |
Why?
|
| Colonic Polyps | 4 | 2022 | 17 | 2.020 |
Why?
|
| Cathartics | 4 | 2018 | 11 | 2.010 |
Why?
|
| Adenoma | 4 | 2022 | 61 | 1.950 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 142 | 1.880 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 122 | 1.050 |
Why?
|
| Gastroenterology | 2 | 2018 | 15 | 0.670 |
Why?
|
| Oxytocin | 1 | 2021 | 6 | 0.660 |
Why?
|
| Colon | 2 | 2018 | 123 | 0.630 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 59 | 0.610 |
Why?
|
| Humans | 31 | 2023 | 29211 | 0.590 |
Why?
|
| Esophageal Stenosis | 1 | 2018 | 3 | 0.570 |
Why?
|
| Male | 21 | 2023 | 14126 | 0.570 |
Why?
|
| Deglutition Disorders | 1 | 2018 | 25 | 0.560 |
Why?
|
| Colonic Diseases | 1 | 2018 | 10 | 0.560 |
Why?
|
| Therapeutic Irrigation | 1 | 2018 | 20 | 0.560 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 8 | 0.550 |
Why?
|
| Duodenal Diseases | 1 | 2018 | 7 | 0.550 |
Why?
|
| Hydralazine | 1 | 2018 | 6 | 0.550 |
Why?
|
| Liver Cirrhosis | 3 | 2018 | 78 | 0.550 |
Why?
|
| Veterans Health | 2 | 2016 | 6 | 0.540 |
Why?
|
| Duodenum | 1 | 2018 | 18 | 0.540 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 42 | 0.540 |
Why?
|
| Female | 19 | 2023 | 15825 | 0.540 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2662 | 0.500 |
Why?
|
| Gastrointestinal Transit | 1 | 2016 | 8 | 0.500 |
Why?
|
| Narcotics | 1 | 2016 | 11 | 0.500 |
Why?
|
| Patient Compliance | 1 | 2017 | 77 | 0.490 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2014 | 44 | 0.480 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 92 | 0.480 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2015 | 134 | 0.480 |
Why?
|
| Liver Neoplasms | 3 | 2015 | 168 | 0.470 |
Why?
|
| Conscious Sedation | 1 | 2015 | 10 | 0.440 |
Why?
|
| Aged | 10 | 2018 | 5648 | 0.440 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 15 | 0.440 |
Why?
|
| Hepatitis C, Chronic | 2 | 2018 | 32 | 0.440 |
Why?
|
| Preoperative Care | 1 | 2015 | 81 | 0.430 |
Why?
|
| Butylscopolammonium Bromide | 1 | 2014 | 2 | 0.430 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 216 | 0.420 |
Why?
|
| Image Enhancement | 1 | 2014 | 59 | 0.420 |
Why?
|
| Pain | 1 | 2016 | 258 | 0.420 |
Why?
|
| Middle Aged | 12 | 2023 | 7495 | 0.410 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 121 | 0.400 |
Why?
|
| Hepatitis C | 2 | 2013 | 42 | 0.390 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 149 | 0.390 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 12 | 0.380 |
Why?
|
| Needles | 1 | 2013 | 26 | 0.380 |
Why?
|
| Mental Disorders | 1 | 2014 | 118 | 0.370 |
Why?
|
| Alanine Transaminase | 2 | 2018 | 27 | 0.350 |
Why?
|
| Stress, Psychological | 1 | 2014 | 234 | 0.340 |
Why?
|
| Video Recording | 1 | 2011 | 41 | 0.340 |
Why?
|
| Glycogen Storage Disease Type VII | 1 | 2011 | 2 | 0.340 |
Why?
|
| Mesenteric Veins | 1 | 2011 | 3 | 0.340 |
Why?
|
| Portal Vein | 1 | 2011 | 8 | 0.340 |
Why?
|
| Gastroscopy | 1 | 2011 | 7 | 0.340 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2011 | 11 | 0.330 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 98 | 0.320 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 19 | 0.310 |
Why?
|
| Catheterization | 1 | 2010 | 50 | 0.310 |
Why?
|
| Pancreatitis | 1 | 2010 | 36 | 0.310 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 94 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 77 | 0.300 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 285 | 0.260 |
Why?
|
| Midazolam | 2 | 2018 | 8 | 0.250 |
Why?
|
| United States | 4 | 2017 | 2270 | 0.250 |
Why?
|
| Biomarkers, Tumor | 3 | 2015 | 417 | 0.250 |
Why?
|
| Comorbidity | 2 | 2018 | 261 | 0.250 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 556 | 0.240 |
Why?
|
| Fentanyl | 2 | 2018 | 35 | 0.240 |
Why?
|
| Risk Factors | 3 | 2018 | 2144 | 0.240 |
Why?
|
| Antiviral Agents | 2 | 2018 | 114 | 0.220 |
Why?
|
| Polyethylene Glycols | 2 | 2016 | 101 | 0.210 |
Why?
|
| Barrett Esophagus | 2 | 2014 | 16 | 0.200 |
Why?
|
| Esophageal Neoplasms | 2 | 2014 | 33 | 0.190 |
Why?
|
| Adult | 8 | 2023 | 8130 | 0.190 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 526 | 0.180 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 139 | 0.180 |
Why?
|
| Cecum | 1 | 2022 | 14 | 0.180 |
Why?
|
| Orexins | 1 | 2021 | 1 | 0.170 |
Why?
|
| Hypothalamus | 1 | 2021 | 29 | 0.170 |
Why?
|
| Veterans | 1 | 2022 | 69 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 301 | 0.160 |
Why?
|
| Eating | 1 | 2021 | 71 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 415 | 0.160 |
Why?
|
| Health Resources | 2 | 2017 | 19 | 0.160 |
Why?
|
| Electric Stimulation | 1 | 2021 | 256 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 484 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 554 | 0.150 |
Why?
|
| Diet | 1 | 2021 | 243 | 0.140 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2018 | 3 | 0.140 |
Why?
|
| Glucagon | 1 | 2018 | 11 | 0.140 |
Why?
|
| Diphenhydramine | 1 | 2018 | 3 | 0.140 |
Why?
|
| Medical Staff, Hospital | 1 | 2018 | 22 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 145 | 0.140 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 16 | 0.140 |
Why?
|
| Operative Time | 1 | 2018 | 41 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 29 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 237 | 0.130 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 4 | 0.130 |
Why?
|
| Rats | 1 | 2021 | 1595 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 14 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2017 | 57 | 0.120 |
Why?
|
| Sex Factors | 1 | 2018 | 473 | 0.120 |
Why?
|
| Gastroenterologists | 1 | 2016 | 6 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 225 | 0.120 |
Why?
|
| Equipment and Supplies | 1 | 2016 | 12 | 0.120 |
Why?
|
| Cost Savings | 1 | 2016 | 20 | 0.120 |
Why?
|
| Research Support as Topic | 1 | 2016 | 11 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2018 | 249 | 0.120 |
Why?
|
| Age Factors | 1 | 2018 | 740 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 55 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2017 | 130 | 0.120 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 13 | 0.120 |
Why?
|
| Dextran Sulfate | 1 | 2015 | 9 | 0.110 |
Why?
|
| Mass Screening | 1 | 2016 | 160 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2014 | 741 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2016 | 99 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 134 | 0.110 |
Why?
|
| Stem Cells | 2 | 2015 | 127 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2015 | 120 | 0.110 |
Why?
|
| Colitis | 1 | 2015 | 54 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 705 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2014 | 1288 | 0.110 |
Why?
|
| Genetic Therapy | 1 | 2015 | 125 | 0.110 |
Why?
|
| Hepatorenal Syndrome | 1 | 2014 | 2 | 0.110 |
Why?
|
| Hepatic Encephalopathy | 1 | 2014 | 5 | 0.110 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2014 | 6 | 0.110 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 5 | 0.110 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2014 | 3 | 0.110 |
Why?
|
| Peritonitis | 1 | 2014 | 15 | 0.100 |
Why?
|
| Ascites | 1 | 2014 | 21 | 0.100 |
Why?
|
| Afghan Campaign 2001- | 1 | 2014 | 11 | 0.100 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2014 | 11 | 0.100 |
Why?
|
| Hyponatremia | 1 | 2014 | 17 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2018 | 2442 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 198 | 0.100 |
Why?
|
| Neoplasms | 1 | 2023 | 888 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2014 | 56 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2013 | 32 | 0.100 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 31 | 0.100 |
Why?
|
| Ribavirin | 1 | 2013 | 9 | 0.100 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 24 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2013 | 65 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2013 | 50 | 0.090 |
Why?
|
| Incidence | 1 | 2014 | 581 | 0.090 |
Why?
|
| Prevalence | 1 | 2014 | 526 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2014 | 467 | 0.090 |
Why?
|
| Indoles | 1 | 2013 | 112 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 794 | 0.090 |
Why?
|
| Virus Diseases | 1 | 2012 | 39 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 305 | 0.090 |
Why?
|
| Time Factors | 2 | 2015 | 1619 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 54 | 0.090 |
Why?
|
| Esophagus | 1 | 2012 | 72 | 0.090 |
Why?
|
| Animals | 3 | 2021 | 10806 | 0.080 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 23 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 151 | 0.080 |
Why?
|
| Bile Ducts | 1 | 2010 | 6 | 0.080 |
Why?
|
| Cachexia | 1 | 2011 | 53 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 33 | 0.080 |
Why?
|
| Quality of Life | 1 | 2013 | 523 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 145 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2015 | 247 | 0.070 |
Why?
|
| Research Design | 1 | 2010 | 188 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 484 | 0.070 |
Why?
|
| Hepacivirus | 2 | 2018 | 49 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 468 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2016 | 903 | 0.050 |
Why?
|
| Occult Blood | 1 | 2023 | 5 | 0.050 |
Why?
|
| Young Adult | 1 | 2011 | 2877 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2015 | 828 | 0.050 |
Why?
|
| Benchmarking | 1 | 2022 | 33 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 817 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 98 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 1013 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 4 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 20 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2018 | 18 | 0.030 |
Why?
|
| Bilirubin | 1 | 2018 | 11 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2018 | 36 | 0.030 |
Why?
|
| Colorectal Surgery | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 11 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 40 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 2016 | 19 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 12 | 0.030 |
Why?
|
| Efficiency | 1 | 2016 | 18 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2016 | 29 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 40 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 483 | 0.030 |
Why?
|
| Publishing | 1 | 2016 | 34 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 93 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 49 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 137 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 111 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 319 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 2014 | 16 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 333 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 276 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 790 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 142 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2014 | 62 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 257 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 466 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 689 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 515 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 473 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 210 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 272 | 0.020 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 3 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 67 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2012 | 14 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 65 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 524 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 2012 | 20 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 2012 | 20 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 784 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 462 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 30 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 417 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 36 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 89 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1362 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 329 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 88 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 154 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1033 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2012 | 159 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 669 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1502 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 4870 | 0.010 |
Why?
|